Roche’s KRAS blocker touts best-in-class NSCLC potential in Phase III trial

Genentech's divarasib posts this win as KRAS-targeting therapies demonstrate ‘game-changing’ potential in hard-to-treat cancers. Divarasib outperformed existing therapies in patients with KRAS G12C non-small cell lung cancer (NSCLC). Divarasib bested Krazati and Lumykras in terms of PFS and OS in a Phase III KRAS G12C-positive NSCLC study. Credit: Net Vector / Shutterstock.com. Roche-owned Genentech’s KRAS G12C inhibitor, divarasib, has outperformed marketed drugs in its class in a Phase III head-to-head study – a result the company says could put the medicine in pole position in the KRAS G12C non-small cell lung cancer (NSCLC) market. Genentech evaluated its next-generation KRAS G12C…

Source: Clinical Trials Arena